Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
I’ah Donovan-Banfield(University of Liverpool), Lara Lavelle-Langham(University of Liverpool), Shazaad Ahmad(Manchester University NHS Foundation Trust), Alistair C. Darby(University of Liverpool), Julian A. Hiscox(University of Liverpool), Xiaofeng Dong(University of Liverpool), William Greenhalf(University of Liverpool), Jack Pilgrim(University of Liverpool), Saye Khoo(University of Liverpool), Richard J. Fitzgerald(University of Limerick), Josh Northey(University Hospital Southampton NHS Foundation Trust), Hannah Goldswain(University of Liverpool), Victoria Shaw(University of Liverpool), Thomas Edwards(Liverpool School of Tropical Medicine), Aleksandra Rzeszutek(University of Liverpool), Helen Reynolds(University of Liverpool), David G. Lalloo(Liverpool School of Tropical Medicine), Miles W. Carroll(Institute of Human Genetics), Emma Knox(University of Southampton), Jimstan Periselneris(King's College Hospital NHS Foundation Trust), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Lauren Walker(University of Liverpool), Yan Ryan(University of Liverpool), Rebekah Penrice-Randal(University of Liverpool), Katie Bullock(University of Liverpool), Gareth Griffiths(NIHR Evaluation Trials and Studies Coordinating Centre), Christie Woods(Royal Liverpool and Broadgreen University Hospital NHS Trust), Michelle Tetlow(University of Liverpool), Colin Hale(Royal Liverpool and Broadgreen University Hospital NHS Trust), Rebecca Lyon(Royal Liverpool and Broadgreen University Hospital NHS Trust), Geoffrey Saunders(University of Southampton), Dennis Hadjiyiannakis(Lancashire Teaching Hospitals NHS Foundation Trust), Calley Middleton(University of Southampton)
Cited by 42
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k